Empiric azithromycin plus β-lactam therapy reduces the composite risk of 30-day mortality and rehospitalization in nonsevere CAP.

AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...

Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...

Please provide your email address to receive an email when new articles are posted on . Smoking abstinence during week 9 to week 12 among adults with COPD was 19.1% with 12-cytisinicline vs. 4.3% with ...

In support of World COPD Day on November 19, the Global Initiative for Chronic Obstructive Lung Disease (GOLD), is drawing attention to the importance of correctly diagnosing COPD earlier - with the ...

Please provide your email address to receive an email when new articles are posted on . Hospitalizations with vs. without pathway use were shorter and cost less. Significantly more ...

AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...

Mass administration of azithromycin to children 1 to 59 months of age has been shown to reduce mortality among infants and children in this age group in some areas of sub-Saharan Africa. The largest ...

Chronic obstructive pulmonary disease, or COPD, is the fourth leading cause of death worldwide, responsible for 3.5 million deaths in 2021, according to the World Health Organization. It’s a common ...

The 5 variables indicating whether azithromycin is likely to prevent AECOPD are white BCC, hemoglobin, CRP, FVC, and respiratory symptoms identified by the SGRQ. An individual treatment effect (ITE) ...

Researchers have found a promising treatment breakthrough for chronic obstructive pulmonary disease (COPD) that avoids many of the drawbacks of current drugs, and it has come from an unexpected place.

Investigators compare efficacy of low- versus high-dose of methylprednisolone in preventing pulmonary lesions in children with severe Mycoplasma pneumoniae pneumonia Mycoplasma pneumoniae infection is ...